<DOC>
	<DOCNO>NCT02656303</DOCNO>
	<brief_summary>This multi-center , open-label , study evaluate safety efficacy ublituximab ( TG-1101 ) combination TGR-1202 patient progressed treatment arm previously enrol Protocol UTX-TGR-304</brief_summary>
	<brief_title>An Open-Label Study Evaluate Safety Efficacy Ublituximab Combination With TGR-1202 Patients Previously Enrolled Protocol UTX-TGR-304</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Prior treatment clinical trial UTXTGR304 Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Patients refractory ublituximab + TGR1202 Transformation CLL aggressive NonHodgkin 's Lymphoma ( NHL ) ( Richter 's transformation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>